Cut-offs for EPOS 2020 biologic indication criteria: type 2 inflammation (tissue eosinophils ≥ 10 cells/HPF, blood eosinophils ≥ 250 cells/μL, or total IgE ≥ 100 IU/mL), need for systemic corticosteroids (≥ 2 courses/year, long-term low-dose use, or contraindication), significantly impaired HRQoL (SNOT-22 ≥ 40), significant loss of smell (anosmia on smell testing), and comorbid asthma (physician-diagnosed). Here, IGHE is linked to asthma.